NeuroSense Therapeutics is preparing to start its Phase 3 PARAGON trial for PrimeC, a treatment for ALS, after FDA clearance. The company is actively securing strategic financing and exploring regulatory approvals, including a planned New Drug Submission in Canada by December 2026, to bring the drug to patients sooner. NeuroSense is also addressing Nasdaq listing compliance and exploring partnerships to support PrimeC's development and commercialization. These efforts aim to accelerate treatment availability for ALS patients while ensuring financial and regulatory readiness.
Coinbase’s wrapped Bitcoin product, cbBTC, has expanded to Robinhood Chain, a new Layer-2 blockchain, through Chainlink’s Cross-Chain Interoperability Protocol (CCIP). This connection allows Bitcoin-backed assets to move seamlessly between Coinbase a...
QuidelOrtho Corporation released episode 60 of its Science Bytes podcast featuring key presentations from the 2026 ADLM Annual Conference. The episode discusses advances in ultra-fast molecular diagnostics, antibiotic stewardship using procalcitonin ...
Target and Lowe's both raised dividends after reporting Q2 earnings, but their financial health differs significantly. Target's small dividend increase reflects caution, supported by a strong balance sheet and a focus on maintaining credit ratings. L...
Bitcoin's price rally in August is encountering a critical resistance zone between $81,000 and $86,000, identified as a major supply area by analysts. This zone includes breakeven points for long-term holders and options-related selling pressure, mak...
The top 50 public companies holding Bitcoin saw their combined market value drop from $150 billion in July 2025 to $67 billion by August 2026, losing $80 billion largely due to Strategy (formerly MicroStrategy). This collapse signals the failure of t...
